Highly innovative drugs in the Czech Republic: retrospective analysis of impact on early market entry, regular reimbursement system entry and public pharmaceutical expenditure
Crossref DOI link: https://doi.org/10.1186/2052-3211-8-S1-O3
Published Online: 2015-10-05
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lukačišinová, Anna
Skácelová, Helena
Text and Data Mining valid from 2015-10-05
Article History
First Online: 5 October 2015